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A B S T R A C T
A retrospective cohort study evaluated the effect-
iveness and nephrotoxicity of intravenous colistin
monotherapy vs. colistin–meropenem combina-
tion therapy for patients with multidrug-resistant
Gram-negative bacterial infections. Fourteen pa-
tients received intravenous colistin monotherapy
and 57 received colistin–meropenem. No signifi-
cant differences were found concerning clinical
response of the infection (12 ⁄ 14 (85.7%) vs. 39 ⁄ 57
(68.4%), p 0.32) and development of nephrotox-
icity (0 ⁄ 14 (0%) vs. 4 ⁄ 57 (7%), p 0.58). A favour-
able association was revealed between survival
and treatment with colistin monotherapy com-
pared to colistin–meropenem (0 ⁄ 14 (0%) vs. 21 ⁄ 57
(36.8%) deaths, p 0.007), even after adjusting for
the variables for which significant differences
were found.
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Most recent clinical studies with polymyxins have
reported data concerning the clinical outcome for
patients treated with combinations of polymyxins
and various other antimicrobial agents [1–5].
However, data concerning the comparative effect-
iveness and toxicity of colistin monotherapy vs.
colistin–b-lactam combination therapy in patients
other than those with cystic fibrosis are lacking.
A retrospective cohort study was conducted
at the tertiary-care Henry Dunant hospital in
Athens, Greece. The study was approved by the
Institutional Review Board of the hospital.
Patients with infections caused by multidrug-
resistant Gram-negative bacilli who were hospi-
talised during the period October 2000 to May
2005 and were managed with intravenous
colistimethate sodium were identified from the
pharmacy electronic databases and included in
the study. Two physicians (PIR and SKK)
reviewed the patients’ records and classified
the outcomes. Patients were excluded from
further analysis if they had received intravenous
colistin therapy for <72 h. This group of patients
was compared with patients treated concomi-
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tantly with colistin and meropenem for at least
50% of the duration of the treatment, or alter-
natively for ‡7 days. For patients who received
colistin monotherapy or colistin–meropenem
combination therapy for more than one episode
of infection, only the first episode was included
in the analysis.
Definitions of episodes of infections and out-
comes, including cure of the infection and neph-
rotoxicity, as well as the microbiological methods
used, have been described previously [3]. Specif-
ically, ‘cure’ was defined as a resolution of
presenting signs and symptoms of infection by
the end of colistin treatment; ‘improvement’ was
defined as a partial resolution of presenting signs
and symptoms; and ‘deterioration’ was defined as
persistence or worsening of presenting signs and
symptoms during colistin administration. ‘Nor-
mal renal function’ was defined as a serum
creatinine level £1.3 mg ⁄dL, with ‘deterioration’
defined as an increase of >50% of the baseline
creatinine level to a value >1.3 mg ⁄dL, or as a
decline in renal function requiring renal replace-
ment therapy. ‘Baseline creatinine’ was defined as
the creatinine level on the initial day of intraven-
ous colistin administration. Intermediate sensitiv-
ity was considered as resistance.
The distribution of variables in the two groups
was analysed using the chi-square test or
Fischer’s exact test for categorical variables, and
Student’s t-test or the Mann–Whitney test for
normally and non-normally distributed continu-
ous variables, respectively. Variables associated
with mortality in the bivariable analysis (p <0.05)
were included in a multiple logistic regression
model.
Of 257 patients who received intravenous
colistin during the study period, 71 qualified for
inclusion in the present analysis. Of these, 14
received colistin monotherapy and 57 received
colistin–meropenem combination therapy. The
mean daily dose of colistin administered to the
monotherapy group was 4.6 ± 2.3 MIU, with
a mean duration of administration of 14.2 ±
7.3 days. In the colistin–meropenem group, the
mean daily dose of colistin was 5.5 ± 2.2 MIU,
with a mean duration of administration of 17.8 ±
11.4 days, and meropenem was administered at a
mean daily dose of 4.8 ± 1.6 g for a mean of
15.7 ± 9.6 days.
Table 1 compares the baseline (non-outcome)
variables in the two groups. No statistically
significant differences were found with respect
to demographical and clinical characteristics,
except that the urinary tract was the site of
infection (p 0.009), and Pseudomonas aeruginosa
(p 0.05) was the responsible pathogen more com-
monly among the colistin monotherapy group
than among the colistin–meropenem group.
No statistically significant difference regarding
clinical response (cure and improvement) of the
infection and occurrence of nephrotoxicity was
found between the two groups (12 ⁄ 14 (85.7%) vs.
Table 1. Comparison of the severity of illness and co-





n = 57a p
Demographical data
Age (years) 56.2 ± 19.8 61.5 ± 18.9 0.43
Gender (male) 8 ⁄ 14 (57.1%) 34 ⁄ 57 (59.6%) 0.86
APACHE II score 14.3 ± 7.4 15.4 ± 6.6 0.56
Co-morbidity
Malignancy 3 ⁄ 14 (21.4%) 10 ⁄ 57 (17.5%) 0.71
Heart dysfunction 8 ⁄ 14 (57.1%) 30 ⁄ 57 (52.6%) 0.76
Lung dysfunction 2 ⁄ 14 (14.3%) 18 ⁄ 57 (31.6%) 0.20
Diabetes mellitus 3 ⁄ 14 (21.4%) 15 ⁄ 57 (26.3%) 0.71
Urogenital disorder 4 ⁄ 14 (28.6%) 14 ⁄ 57 (24.6%) 0.76
Chronic renal failure 0 ⁄ 14 (0%) 6 ⁄ 57 (10.5%) 0.59
Hepatic disease 0 ⁄ 14 (0%) 6 ⁄ 57 (10.5%) 0.59
Haematological disorder 2 ⁄ 14 (14.3%) 3 ⁄ 57 (5.3%) 0.25
Neurological disorder 8 ⁄ 14 (57.1%) 18 ⁄ 57 (31.6%) 0.08
Previous hospitalisation 10 ⁄ 14 (71.4%) 37 ⁄ 57 (64.9%) 0.64
Previous antibiotic use 10 ⁄ 14 (71.4%) 33 ⁄ 57 (57.9%) 0.35
Previous surgery 8 ⁄ 14 (57.1%) 34 ⁄ 57 (59.6%) 0.86
Duration of hospitalisation
before the first day of
colistin treatment (days)
23.3 ± 37.1 16.5 ± 12.0 0.69
Admission to the ICU 11 ⁄ 14 (78.6%) 52 ⁄ 57 (91.2%) 0.18
Duration of ICU stay (days) 10.5 ± 11.5 17.2 ± 18.6 0.69
Mechanical ventilation support 7 ⁄ 14 (50%) 36 ⁄ 57 (63.2%) 0.37
Special treatments 10 ⁄ 14 (71.4%) 47 ⁄ 57 (82.5%) 0.45
Anti-tumour treatment 1 ⁄ 14 (7.1%) 4 ⁄ 57 (7%) 1
Steroid treatment 5 ⁄ 14 (35.7%) 22 ⁄ 57 (38.6%) 0.84
Blood transfusion 9 ⁄ 14 (64.3%) 40 ⁄ 57 (70.2%) 0.75
Haemodialysis 2 ⁄ 14 (14.3%) 9 ⁄ 57 (15.8%) 1
Urinary catheter 14 ⁄ 14 (100%) 46 ⁄ 57 (80.7%) 0.11
Gastrostomy ⁄ colostomy 1 ⁄ 14 (7.1%) 1 ⁄ 57 (1.8%) 0.36
Type of infection
Pneumonia 6 ⁄ 14 (42.9%) 23 ⁄ 57 (40.4%) 0.86
Urinary tract infection 4 ⁄ 14 (28.6%) 3 ⁄ 57 (5.3%) 0.009
Abdominal 2 ⁄ 14 (14.3%) 5 ⁄ 57 (8.8%) 0.62
Spondylodiscitis 1 ⁄ 14 (7.1%) 1 ⁄ 57 (1.8%) 0.36
Surgical site infection ⁄ skin
and soft-tissue infection
0 ⁄ 14 (0%) 3 ⁄ 57 (5.3%) 1
Bacteremia 1 ⁄ 14 (7.14%) 16 ⁄ 57 (28.1%) 0.16
Catheter-related 0 ⁄ 14 (0%) 5 ⁄ 57 (8.8%) 0.58
Empirical 0 ⁄ 14 (0%) 1 ⁄ 57 (1.8%) 1
Pathogen isolatedb
Acinetobacter baumannii 5 ⁄ 17 (29.4%) 32 ⁄ 58 (55.2%) 0.06
Pseudomonas aeruginosa 9 ⁄ 17 (52.9%) 16 ⁄ 58 (27.6%) 0.05
Klebsiella pneumoniae 2 ⁄ 17 (11.8%) 7 ⁄ 58 (12.1%) 1
Stenotrophomonas maltophilia 1 ⁄ 17 (5.9%) 0 ⁄ 58 (0.0%) 0.23
Enterobacter cloacae 0 ⁄ 17 (0%) 1 ⁄ 58 (1.7%) 1
Escherichia coli 0 ⁄ 17 (0%) 1 ⁄ 58 (1.7%) 1
None 0 ⁄ 17 (0%) 1 ⁄ 58 (1.7%) 1
Antimicrobial susceptibility
Multidrug-resistant 7 ⁄ 17 (41.2%) 32 ⁄ 58 (55.2%) 0.31
Susceptible only to polymyxin 10 ⁄ 17 (58.8%) 26 ⁄ 58 (44.8%) 0.41
an refers to the first episode of infection for which patients received colistin
monotherapy or the combination of colistin and meropenem.
bThe denominator refers to the number of pathogens isolated from the 57 patients.
From one patient, two microorganisms were isolated from a single specimen; thus
58 was the total number of responsible pathogens.
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39 ⁄ 57 (68.4%), p 0.32, and 0 ⁄ 14 (0%) vs. 4 ⁄ 57
(7%), p 0.58, respectively). In-hospital mortality
was less common among the colistin monothera-
py group than among the colistin–meropenem
group (0 ⁄ 14 (0%) vs. 21 ⁄ 57 (36.8%), p 0.007). The
favourable association between colistin mono-
therapy and survival remained even after adjust-
ing for these two variables, for which statistically
significant differences were found in the bivaria-
ble analyses.
In an era of expanding antimicrobial resistance,
the use of colistin for the treatment of infections
caused by Gram-negative bacteria has re-
emerged. The safety and effectiveness of colistin
have been questioned in the past, and its use was
restricted mainly to patients with cystic fibrosis
[6,7]. The present retrospective comparative study
sought to evaluate the safety and effectiveness of
colistin monotherapy and colistin–meropenem
combinations in the treatment of infections
caused by multidrug-resistant Gram-negative
bacteria. The main finding of the study was that
colistin monotherapy was not inferior to colistin–
meropenem therapy with respect to cure of the
infection and nephrotoxicity. Indeed, better sur-
vival was noted in patients treated with colistin
monotherapy, and this association remained even
after adjusting for the variables for which statis-
tically significant differences between the
compared groups were found (i.e., site of infec-
tion and pathogen).
Four patients in the colistin–meropenem group
experienced nephrotoxicity and three died. Devel-
opment of acute renal failure, especially in critic-
ally-ill patients, is associated with increased
mortality [8,9], and deterioration of renal function
of any pathogenesis during intravenous colistin
treatment, in addition to an age of >50 years, was
found to be associated independently with mor-
tality in a study of 43 patients with Gram-negative
bacterial infections [4]. This may partially explain
the difference in rates of mortality observed in the
present study, although the small sample size
meant that a significant association was not
detected. In addition, there was a predominance
of urinary tract infections among the colistin
monotherapy group, compared with more severe
infections among the colistin–meropenem group.
It should be noted that combinations of colistin
with various antimicrobial agents have been
reported to have in-vitro synergic activity against
multidrug-resistant Gram-negative bacteria [6,10].
Synergic activity of colistin with ceftazidime
against P. aeruginosa has also been reported in
an in-vitro study, as well as with rifampicin
against P. aeruginosa and Acinetobacter baumannii
strains [11,12].
The retrospective nature and the relatively
small number of patients treated with colistin
monotherapy were the main shortcomings of the
present analysis. In addition, there were too few
patients to examine the comparative effectiveness
and toxicity of colistin in combination with
antibiotics other than meropenem, and microbio-
logical synergy studies of colistin with merope-
nem were not performed.
In conclusion, the effectiveness of colistin
monotherapy did not appear to be inferior to that
of colistin–meropenem combination therapy for
patients with multidrug-resistant bacterial
infections. These limited and preliminary data
provide support for further studies of colistin
monotherapy in this patient population.
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A B S T R A C T
Methicillin-resistant coagulase-negative staphylo-
cocci (MR-CNS) (n = 132), isolated from pre-term
neonates, were analysed to determine their anti-
biotic resistance patterns, clonal distribution,
biofilm production and the presence of the ica
operon. All MR-CNS were multiresistant, and
89% produced slime. A major clone was identi-
fied (77 isolates) among 115 Staphylococcus epider-
midis isolates. Ten of 16 Staphylococcus haemolyti-
cus isolates also belonged to a single clone. Most
(80%) slime-positive isolates possessed all the ica
genes tested, while the remaining 23 (20%) had a
variety of gene combinations. The entire ica
cluster was detected in three of 15 slime-negative
isolates. One major and two minor slime-positive,
multiresistant MR-CNS clones had disseminated
among hospitalised pre-term neonates.
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Biochemical and molecular typing studies have
demonstrated that clusters of coagulase-negative
staphylococci (CNS) may be distributed among
both neonates and hospital staff, while isolates
associated with sepsis may be more homogeneous
[1–3]. CNS are recognised as potential pathogens
because they produce slime and form biofilms on
polymeric surfaces [4–6]. Several reports have
described the chemical composition of slime [5–
7]. Production of an extracellular polysaccharide
intercellular adhesin is encoded by the genes of
the ica operon (icaA, icaD, icaB and icaC), regula-
ted by icaR [4–6]. Absence of biofilm formation
has been associated with inactivation of either
icaA or icaC following insertion of IS256, which
resides in multiple copies on the chromosome of
staphylococci [6]. The present study investigated
the clonal dissemination of multiresistant, meth-
icillin-resistant (MR)-CNS isolates in the neonatal
intensive care unit (NICU) of the Patras Univer-
sity Hospital during 2003–2004, and correlated the
presence of the ica operon and IS256 with biofilm
production and disease.
In total, 132 MR-CNS isolates were collected
from the pre-term NICU, which has 25 beds and
admits 350 patients annually. Thirty-one isolates
were from blood cultures of different patients
with CNS sepsis, as defined by well-established
criteria [8], 18 were from intravascular catheter
tips with systemic evidence of infection [9,10], 28
were recovered as the only microorganism from
skin lesions in which Gram-positive cocci and
polymorphonuclear leukocytes were observed
upon microscopic examination, and 55 were
collected from ventilation tubes; the latter were
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